SCHEMBL32667337

SCHEMBL32667337

CC1(C)CCC(C(=O)N2CC3(CNC3)C2)=C(c2ccc(Cl)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.38
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
IDH1 O75874 1/20 0.35
BCL2 P10415 2/20 0.35
SLC6A3 Q01959 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GPR183 P32249 2/20 0.33
SLC6A2 P23975 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
HSD11B1 P28845 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
NAMPT P43490 1/20 0.33
JAK1 P23458 1/20 0.33
ENPP2 Q13822 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32667638 0.90 BCL2L1 (0.40) BCL2L1PTGS1PTGS2BCL2SLC6A3
SCHEMBL32667516 0.89 HDAC2 (0.39) PTGS1PTGS2GPR183HSD11B1PIK3CA
SCHEMBL30851284 0.85 SCN5A (0.48) BCL2L1PTGS1PTGS2BCL2SLC6A3
SCHEMBL32667347 0.81 SCN5A (0.45) BCL2L1PTGS1PTGS2BCL2SLC6A3
SCHEMBL32667388 0.81 CHRNA4 (0.42) BCL2L1
SCHEMBL32667589 0.80 BCL2L1 (0.38) BCL2L1PTGS1PTGS2BCL2SLC6A3
SCHEMBL32667718 0.79 BCL2L1 (0.38) BCL2L1PTGS1PTGS2IDH1BCL2
SCHEMBL32667380 0.79 NAMPT (0.42) PTGS1PTGS2GPR183HSD11B1PIK3CA
SCHEMBL32667526 0.76 BCL2L1 (0.38) BCL2L1PTGS1PTGS2IDH1BCL2
SCHEMBL32667351 0.76 BCL2L1 (0.38) BCL2L1PTGS1PTGS2IDH1BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) 2026-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF CDR2, CYC1, CLN6 BCL2L1 346/4885PTGS1 584/4885PTGS2 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.